Clinical Trial Update: Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating QL1706 in combination with olaparib for previously treated homologous recombination repair-deficient recurrent or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)
• QL1706

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Triple-Negative Breast Cancer (TNBC) | Phase 2 | Status: NOT_YET_RECRUITING